2015
DOI: 10.1039/c5ob01843a
|View full text |Cite
|
Sign up to set email alerts
|

Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1

Abstract: Dimethylarginine dimethylaminohydrolase (DDAH) is a key enzyme involved in the metabolism of asymmetric dimethylarginine (ADMA) and N-monomethyl arginine (NMMA), which are endogenous inhibitors of the nitric oxide synthase (NOS) family of enzymes. Two isoforms of DDAH have been identified in humans, DDAH-1 and DDAH-2. DDAH-1 inhibition represents a promising strategy to limit the overproduction of NO in pathological states without affecting the homeostatic role of this important messenger molecule. Here we des… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
28
0

Year Published

2017
2017
2025
2025

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 20 publications
(28 citation statements)
references
References 66 publications
0
28
0
Order By: Relevance
“…Over the last two decades various different classes of DDAH1 inhibitors have been synthesized; these exhibit different structures, features and mechanisms of action, and have been previously extensively reviewed (244). Whilst some of these molecules have structural similarity with the DDAH substrates (methylated arginines) (183,(245)(246)(247)(248)(249), others bear a very different chemical structure (56, [250][251][252]. A comprehensive discussion on all DDAH inhibitors synthesized to date and their impact on endothelial cells falls outside the scope of this review, however, here we summarize a small body of evidence that identifies the therapeutic potential for pharmacological inhibition of DDAH1 in cancer.…”
Section: Pharmacological Inhibition Of Ddah1 Activity In Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…Over the last two decades various different classes of DDAH1 inhibitors have been synthesized; these exhibit different structures, features and mechanisms of action, and have been previously extensively reviewed (244). Whilst some of these molecules have structural similarity with the DDAH substrates (methylated arginines) (183,(245)(246)(247)(248)(249), others bear a very different chemical structure (56, [250][251][252]. A comprehensive discussion on all DDAH inhibitors synthesized to date and their impact on endothelial cells falls outside the scope of this review, however, here we summarize a small body of evidence that identifies the therapeutic potential for pharmacological inhibition of DDAH1 in cancer.…”
Section: Pharmacological Inhibition Of Ddah1 Activity In Cancermentioning
confidence: 99%
“…More recently, the potential therapeutic benefit of inhibiting DDAH1 was demonstrated for breast cancer (55). DDAH1 activity was inhibited in triple negative breast cancer cell lines by the potent DDAH1 inhibitors, arginine analogs ZST316 and ZST152 (244,249), as identified by increased intracellular ADMA concentrations and decreased intracellular L-citrulline concentrations (55). In an in vitro Matrigel tube formation model of VM, both ZST316 and ZST152 significantly inhibited the number of vessel-like networks formed at concentrations above 1 µM (55).…”
Section: Pharmacological Inhibition Of Ddah1 Activity In Cancermentioning
confidence: 99%
“…2). Inhibition with the known DDAH1 inhibitor ZST316 was 72% 18 .
Figure 2Concentration dependent inhibition of DDAH1 by ZST316 (positive control), esomeprazole (EPZ), lansoprazole (LPZ), omeprazole (OPZ), pantoprazole (PPZ) and rabeprazole (RPZ). Residual DDAH1 activity is reported as percentage of control activity.
…”
Section: Resultsmentioning
confidence: 99%
“…DDAH1 over-expression was performed as reported by Tommasi et al . 18 A single batch of lysate prepared from DDAH1-expressing HEK293Tcells was used for all in vitro experiments.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation